Drugs / rVSV∆G-ZEBOV-GP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06100913 | Aug 2024 → Aug 2027 expected | Ebola hemorrhagic fever | Emory University | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06587503 | Oct → Dec 2024 overdue | COVID-19, Ebola hemorrhagic fever | University of Birmingham | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-11-13 | Merck Sharp & Dohme LLC | Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration merck.com ↗ |
| 2018-05-30 | Merck Sharp & Dohme LLC | Merck Makes Shipments of Investigational Ebola Zaire Vaccine V920 (rVSV∆G-ZEBOV-GP) to World Health Organization merck.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rVSV∆G-ZEBOV-GP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06100913 ↗ |
| Known as | Recombinant Vesicular Stomatitis Vaccine for Ebola | “Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)” NCT06100913 ↗ |
| Modality | Vaccine | “single dose of an Ebola vaccine” NCT06100913 ↗ |
| Route | Intramuscular | “administered intramuscularly in the deltoid muscle” NCT06100913 ↗ |